3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
11
Recruiting
3
Active not recruiting
2
Withdrawn
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Breast Neoplasms
10
Pancreatic Neoplasms
8
Colorectal Neoplasms
8
Rectal Neoplasms
7
Neoplasm Metastasis
4
Colorectal Cancer Metastatic
4
Stomach Neoplasms
3
Ovarian Neoplasms
3
Colonic Neoplasms
3
Triple Negative Breast Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Gallbladder Neoplasms
2
Carcinoma, Merkel Cell
2
Biliary Tract Neoplasms
2
Zollinger-Ellison Syndrome
1
Vipoma
1
Vaginal Neoplasms
1
Uterine Cervical Neoplasms
1
Urologic Neoplasms
1
Somatostatinoma
1
Sarcoma
1
Prostatic Neoplasms
1
Pheochromocytoma
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Non functioning pancreatic endocrine tumor
1
Neuroendocrine Tumors
1
Neoplasms, Unknown Primary
1
Multiple Endocrine Neoplasia Type 2b
1
Multiple Endocrine Neoplasia Type 2a
1
Multiple Endocrine Neoplasia Type 1
1
Interventions
Cisplatin
3
Fluorouracil
2
Carboplatin
2
pembrolizumab
1
epacadostat
1
Pemetrexed
1
Paclitaxel
1
Oxaliplatin
1
Nivolumab
1
Gemcitabine
1
Cetuximab
1
Capecitabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Parkinson Disease 4, Autosomal Dominant Lewy Body
×
Capecitabine
×
Clear all
NCT04859582
2021-12-16
KEYNOTE-859
Merck Sharp & Dohme LLC
Phase 3
Withdrawn